Steroids in Children Hospitalized With Asthma

Phase 4

Terminated

• Conditions: Asthma; Status Asthmaticus; Wheezes
• Interventions: Drug: Dexamethasone; Drug: Prednisone

• Registration Number: NCT02780479
• Lead Sponsor: University of Florida

Brief Summary

Asthma is the most common chronic disease of children. A short (3-5 day) course of a short-acting steroid such as Prednisone or Prednisolone has long been the standard of care for asthma exacerbation. Dexamethasone efficacy in asthma exacerbation has been studied in the outpatient setting and was found to be as effective as Prednisone. Dexamethasone has the advantage of shorter course, more compliance, and more tolerable. This has led many emergency departments to provide a 1-2 dose course of Dexamethasone on discharge. Thus, many inpatients have received a first dose of Dexamethasone prior to reaching the inpatient unit, leading to confusion about the best plan for these patients. Many hospitalist pediatricians continue to give a 5-day total course with Prednisone, but some patients have begun to receive a second dose of Dexamethasone 24 hours after the first dose. To our knowledge, no studies have been done to compare the efficacy of these two protocols in pediatric patients requiring hospitalization. The hypothesis is that a second dose of Dexamethasone is as effective as four additional days of Prednisone in hospitalized children with asthma exacerbation. This is an open label, randomized control study comparing these treatments in children age 2-18 hospitalized with asthma exacerbation who have received a first dose of Dexamethasone.

Detailed Description

Corticosteroids are the first-line therapy for managing acute asthma exacerbations. Studies have shown that systemic steroids effect decrease relapse and hospital admission. Due to its short half-life, Prednisone is usually given daily or twice daily for 3-5 days. It has been associated with poor compliance due it the prolonged course. Dexamethasone half-life is 36 - 72 hours.

Several studies have shown no difference in outcomes between 3-5 days of prednisone and different forms of dexamethasone, including single intramuscular dose or single oral dose or two oral doses 1 day apart. However, those studies were done in the emergency department (ED). Lack of response to initial asthma treatment in ED results in admission to the hospital, implying more severe exacerbation than those able to be discharged. Some clinician shift to oral prednisone once admitted to the floor for patients who have received Dexamethasone or not. Others have begin to complete the Dexamethasone course with one more dose of Dexamethasone 24 hour after the first dose. Dexamethasone has the advantage of compliance and tolerability, however, no studies investigated its efficacy in hospitalized patients. Such knowledge will improve patient's compliance and outcomes.

* Sample size calculation: Primary outcome of return to normal activities within 3 days of discharge. Based on previous studies, it is estimated that 70% of the control group will achieve this goal. Based on a minimum absolute difference of 15%, and a power of 0.80, the sample size calculated to be 117 in each arm. Assuming 20% lost to follow up, it is intended to recruit 150 in each arm (total 300 subjects).

* Statistical Analysis: Demographics will be analyzed to ensure the experimental and control groups are equivalent at baseline. All proportions will be tested with Chi-square or Fisher exact test and two-sample T-test will be used for continuous variables. α = 0.05 will be used for all hypothesis tests. Interim analysis will be performed monthly and the study will be halted if any safety concerns arise. The Center for Health Equity and Quality Research (CHEQR) will help with statistical analysis

* Data Safety and Monitoring Plan: The study PI and co-investigator will meet and review the collected data on a monthly basis and identify any interim results that may require a change of study protocol. Information that may affect subjects' safety will be communicated to appropriate parties in a timely fashion.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-05-19
• Study First Submitted QC: 2016-05-19
• Study First Posted: 2016-05-23
• Study Start: 2017-03-20
• Primary Completion: 2017-08-29
• Study Completion: 2017-08-29
• Status Verified: 2019-06
• Last Update Submitted: 2019-06-20
• Last Update Posted: 2019-06-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Signed informed consent by legal guardian
• Age 2 to 18 years old
• Admission to the floor with acute asthma exacerbation.
• Received single dose of oral Dexamethasone
• Initial Pediatric Asthma Score (PAS) of 8 or higher.

Read More

Exclusion Criteria

• Admission to PICU
• Recent steroid use (within 1 month)
• Cardiac disorder, chronic respiratory illness (BPD or CF)
• Stridor
• Bacterial Pneumonia

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dexamethasone	Dexamethasone	Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
Prednisone	Prednisone	Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.

Primary Outcome Measures

Name	Time	Method
Return to normal activity (Patient Self-Assessment Score)	3 days after discharge	Proportion of patients who have returned to normal activity

Secondary Outcome Measures

Name	Time	Method
Asthma symptoms (Patient Self-Assessment Score)	2 weeks after discharge	Patient self assessment score at 2 weeks after discharge
Relapse ( ED visit or unscheduled physician visit)	2 weeks after discharge	Proportion of patients with unscheduled primary care physician visits, emergency department or hospital admission
Albuterol use (Patient Self-Assessment Score)	2 weeks after discharge	Proportion of patients with of ongoing albuterol use (based on validated self-reporting tool)

Trial Locations

Locations (1)

Wolfson Children Hospital; 🇺🇸 Jacksonville, Florida, United States